{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:49:40Z","timestamp":1761058180996},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,4,30]],"date-time":"2003-04-30T00:00:00Z","timestamp":1051660800000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Services Research"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:p><jats:bold>Objective. <\/jats:bold> To evaluate the impact of managed care on the use of chronic disease medications.<\/jats:p><jats:p><jats:bold>Data Source. <\/jats:bold> Claims data from 1997 from two indemnity and three independent practice association (IPA) model managed care insurance plans.<\/jats:p><jats:p><jats:bold>Research Design. <\/jats:bold> Cross\u2010sectional analysis of claims data.<\/jats:p><jats:p><jats:bold>Data Collection. <\/jats:bold> Adult patients with diabetes mellitus (DM, <jats:italic>n<\/jats:italic>=26,444), congestive heart failure (CHF, <jats:italic>n<\/jats:italic>=7,978), and asthma (<jats:italic>n<\/jats:italic>=9,850) were identified by ICD\u20109 codes. Chronic disease medication use was defined through pharmacy claims for patients receiving one or more prescriptions for drugs used in treating these conditions. Using multiple logistic regression we adjusted for patient case mix and the number of primary care visits.<\/jats:p><jats:p><jats:bold>Principal Findings. <\/jats:bold> With few exceptions, managed care patients were more likely to use chronic disease medications than indemnity patients. In DM, managed care patients were more likely to use sulfonylureas (43 percent versus 39 percent for indemnity), metformin (26 percent versus 18 percent), and troglitazone (8.8 percent versus 6.4 percent), but not insulin. For CHF patients, managed care patients were more likely to use loop diuretics (45 percent versus 41 percent), ACE inhibitors or angiotensin receptor blockers (50 percent versus 41 percent), and beta\u2010blockers (23 percent versus 16 percent), but we found no differences in digoxin use. In asthma, managed care patients were more likely to use inhaled corticosteroids (34 percent versus 30 percent), systemic corticosteroids (18 percent versus 16 percent), short\u2010acting beta\u2010agonists (42 percent versus 33 percent), long\u2010acting beta\u2010agonists (9.9 percent versus 8.6 percent), and leukotriene modifiers (5.4 percent versus 4.1 percent), but not cromolyn or methylxanthines. Statistically significant differences remained after multivariate analysis that controlled for age, gender, and severity.<\/jats:p><jats:p><jats:bold>Conclusions. <\/jats:bold> Chronic disease patients in these managed care plans are more likely to receive both inexpensive and expensive medications. Exceptions included older medications partly supplanted by newer therapies. Differences may be explained by the fact that patients in indemnity plans face higher out\u2010of\u2010pocket costs and managed care plans promote more aggressive medication use. The relatively low likelihood of condition\u2010specific medications in both plan types is a matter of concern, however.<\/jats:p>","DOI":"10.1111\/1475-6773.00135","type":"journal-article","created":{"date-parts":[[2004,12,25]],"date-time":"2004-12-25T01:21:12Z","timestamp":1103937672000},"page":"595-612","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chronic Disease Medication Use in Managed Care and Indemnity Insurance Plans"],"prefix":"10.1111","volume":"38","author":[{"given":"Randall S.","family":"Stafford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Miracle\u2010McMahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybil L.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,30]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Agency for Health Care Policy and Research.1994. \u201cHeart Failure: Management of Patients with Left Ventricular Systolic Dysfunction.\u201dPublication no. 94\u20100613. Rockville MD:Agency for Health Care Policy and Research."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80011-4"},{"issue":"9","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1161\/01.CIR.92.9.2764","article-title":"Guidelines for the Evaluation and Management of Heart Failure","volume":"92","author":"Committee on Evaluation and Management of Heart Failure","year":"1995","journal-title":"Circulation"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.19.1.203"},{"key":"e_1_2_7_6_1","volume-title":"Guide to the Diagnostic Cost Groups (DCGs) and DxCG Software, Release 4.1","author":"DxCG, Inc","year":"1999"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04960-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.1.210"},{"issue":"2","key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J013v26n02_01","article-title":"The Treatment of Women with Mental Health Disorders under HMO and Fee\u2010for\u2010Service Insurance","volume":"26","author":"Glied S.","year":"1997","journal-title":"Women and Health"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.3.342"},{"issue":"2","key":"e_1_2_7_11_1","first-page":"409","article-title":"Update on Digoxin Therapy in Congestive Heart Failure","volume":"62","author":"Haji S. A.","year":"2000","journal-title":"American Family Physician"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.8.833"},{"key":"e_1_2_7_13_1","article-title":"Backlash Builds over Managed Care","author":"Hilzenrath D. S.","year":"1997","journal-title":"Washington Post"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc4901.102568"},{"issue":"6","key":"e_1_2_7_15_1","first-page":"499","article-title":"Beta\u2010blockers to Reduce Mortality in Patients with Systolic Dysfunction","volume":"50","author":"Lee S.","year":"2001","journal-title":"Journal of Family Practice"},{"issue":"9","key":"e_1_2_7_16_1","first-page":"1747","article-title":"Oral Agents in the Management of Type 2 Diabetes Mellitus","volume":"63","author":"Luna B.","year":"2001","journal-title":"American Family Physician"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.1999.tb00001.x"},{"issue":"19","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.1994.03510430066037","article-title":"Managed Care Plan Performance Since 1980","volume":"271","author":"Miller R. H.","year":"1994","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.16.5.7"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.21.4.63"},{"key":"e_1_2_7_21_1","volume-title":"The State of Managed Care Quality","author":"National Committee for Quality Assurance","year":"1999"},{"key":"e_1_2_7_22_1","unstructured":"National Heart Lung and Blood Institute.1997. \u201cNational Asthma Education and Prevention Program Expert Panel Report 2:Guidelines for the Diagnosis and Management of Asthma.\u201d NIH publication no. 97\u20104051. Bethesda MD:National Heart Lung and Blood Institute."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.89.7.1003"}],"container-title":["Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1475-6773.00135","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1475-6773.00135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T15:32:21Z","timestamp":1697211141000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1475-6773.00135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1111\/1475-6773.00135"],"URL":"https:\/\/doi.org\/10.1111\/1475-6773.00135","archive":["Portico"],"relation":{},"ISSN":["0017-9124","1475-6773"],"issn-type":[{"value":"0017-9124","type":"print"},{"value":"1475-6773","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]},"assertion":[{"value":"2003-04-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}